| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHINTE.159.21.2542 |
| P698 | PubMed publication ID | 10573044 |
| P2093 | author name string | A Weaver | |
| J Caldwell | |||
| S Cohen | |||
| F Hurley | |||
| R Fox | |||
| V Strand | |||
| M Schiff | |||
| D Furst | |||
| J Sharp | |||
| R Fleischmann | |||
| G Cannon | |||
| N Olsen | |||
| L Moreland | |||
| I Loew-Friedrich | |||
| J Kaine | |||
| P433 | issue | 21 | |
| P921 | main subject | methotrexate | Q422232 |
| rheumatoid arthritis | Q187255 | ||
| placebo | Q269829 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 2542-2550 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group | |
| P478 | volume | 159 |
| Q28188829 | A clinical and economic review of disease-modifying antirheumatic drugs |
| Q34413330 | A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis |
| Q35554448 | A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate |
| Q35638735 | Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment |
| Q35552648 | Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures |
| Q35102474 | Advances in the medical treatment of rheumatoid arthritis |
| Q36408155 | Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities |
| Q42209993 | BK Virus and Its Role in Hematopoietic Stem Cell Transplantation: Evolution of a Pathogen |
| Q26859476 | BK virus-associated hemorrhagic cystitis after pediatric stem cell transplantation |
| Q37633519 | Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing |
| Q47199326 | Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo |
| Q38115190 | Can bone loss in rheumatoid arthritis be prevented? |
| Q37000103 | Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? |
| Q34730722 | Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis |
| Q39993473 | Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis |
| Q37895016 | Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years |
| Q37208447 | Chronic Diarrhea Associated with High Teriflunomide Blood Concentration |
| Q51313776 | Circulating IL-27 Is Elevated in Rheumatoid Arthritis Patients. |
| Q38760596 | Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey |
| Q28205716 | Clinical pharmacokinetics of leflunomide |
| Q74209980 | Combination therapy in rheumatoid arthritis |
| Q34309757 | Combination therapy: the risks of infection and tumor induction |
| Q57329990 | Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials |
| Q35638194 | Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis |
| Q34731287 | Current and future management approaches for rheumatoid arthritis |
| Q90030504 | Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials |
| Q45163764 | Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. |
| Q93154989 | Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis-A Network Meta-Analysis of 36 Randomized Controlled Trials |
| Q41849103 | Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis |
| Q37078048 | Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. |
| Q35555116 | Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis |
| Q38101004 | Drugs in development for relapsing multiple sclerosis |
| Q35933703 | Durability and rapidity of response to anakinra in patients with rheumatoid arthritis |
| Q26859134 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update |
| Q36563395 | Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials |
| Q43871018 | Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial |
| Q90287446 | Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT |
| Q38993229 | Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis |
| Q36062038 | Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis |
| Q37480062 | Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide |
| Q51798522 | Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis. |
| Q35551908 | Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. |
| Q35620336 | Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors |
| Q44062289 | Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: comment on the article by van Ede et al. |
| Q73202483 | Folic acid supplementation and methotrexate efficacy: comment on articles by Schiff, Emery et al, and others |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q90597865 | HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis |
| Q40382073 | Herb Network Analysis for a Famous TCM Doctor's Prescriptions on Treatment of Rheumatoid Arthritis |
| Q84593092 | High incidence of intolerance to tuberculosis chemoprophylaxis |
| Q34149748 | Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial. |
| Q46011235 | IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide. |
| Q34484801 | Immunosuppressive Medications |
| Q38063197 | Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia |
| Q33661406 | In vitro inhibition of HUVECs by low dose methotrexate - insights into oral adverse events |
| Q74023929 | Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients |
| Q52583114 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. |
| Q24791754 | Internet hand x-rays: A comparison of joint space narrowing and erosion scores (Sharp/Genant) of plain versus digitized x-rays in rheumatoid arthritis patients |
| Q30804224 | Interpreting radiographic data in rheumatoid arthritis |
| Q43775774 | Is there a place for leflunomide in the treatment of rheumatoid arthritis? |
| Q46602549 | Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment |
| Q36484975 | Leflunomide and warfarin interaction: case report and review of the literature |
| Q44828173 | Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. |
| Q35826170 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice |
| Q55540665 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. |
| Q43767011 | Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study |
| Q33956623 | Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study |
| Q35826792 | Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation |
| Q83879223 | Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery |
| Q97681366 | Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study |
| Q45954946 | Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. |
| Q36703401 | Leflunomide-induced chronic cough in a rheumatoid arthritis patient with pulmonary tuberculosis |
| Q41946145 | Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study |
| Q33826225 | Leflunomide: a review of its use in active rheumatoid arthritis |
| Q28274721 | Leflunomide: friend or foe for systemic lupus erythematosus? |
| Q24675005 | Leflunomide: mode of action in the treatment of rheumatoid arthritis |
| Q28364465 | Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes |
| Q36013828 | Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score |
| Q37258347 | Limits of add-on trials: antirheumatic drugs |
| Q35999549 | Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer? |
| Q36107389 | Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis |
| Q41808826 | Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity |
| Q82338462 | Metabolism studies of a small-molecule tumor necrosis factor-alpha (TNF-α) inhibitor, UTL-5b (GBL-5b) |
| Q24194047 | Methotrexate for treating rheumatoid arthritis |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q46456972 | Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency |
| Q41912381 | Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q53875106 | New Therapies for Rheumatoid Arthritis. |
| Q44518215 | New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval |
| Q36088346 | New therapies for rheumatoid arthritis |
| Q34585191 | Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy |
| Q38071925 | Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. |
| Q30896344 | Number needed to treat (NNT): implication in rheumatology clinical practice |
| Q34637331 | Pathogenesis of bone lesions in rheumatoid arthritis |
| Q35553503 | Patient preferences for treatment of rheumatoid arthritis. |
| Q24791246 | Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study |
| Q52349399 | Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. |
| Q35834289 | Pharmacogenetic approaches to rheumatoid arthritis |
| Q88790397 | Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective |
| Q35198225 | Pharmacological treatment of established rheumatoid arthritis |
| Q35741762 | Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients |
| Q36773117 | Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. |
| Q34732733 | Polyomavirus BK infection in blood and marrow transplant recipients |
| Q35826806 | Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis |
| Q46801582 | Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis |
| Q79603683 | Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone |
| Q43749375 | Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction |
| Q40527567 | Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report |
| Q37786625 | RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis |
| Q31935385 | Radiography of rheumatoid arthritis in the time of increasing drug effectiveness |
| Q64109180 | Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54 |
| Q37397646 | Randomized controlled trial design in rheumatoid arthritis: the past decade |
| Q37358239 | Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis |
| Q37235715 | Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| Q74541001 | Rheumatoid arthritis |
| Q34276012 | Rheumatoid arthritis. Treatment of early disease |
| Q55025616 | Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. |
| Q37812847 | Rheumatologic Disease and the Liver |
| Q53413570 | Rheumatology, geriatrics, and a way forward. |
| Q61815016 | Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis |
| Q36014642 | Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q35953478 | Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. |
| Q33653945 | Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants |
| Q46862184 | Severe hepatotoxicity in a rheumatoid arthritis patient switched from leflunomide to methotrexate. |
| Q51752628 | Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study. |
| Q35915958 | Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? |
| Q43685328 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine |
| Q40459804 | Spontaneous multiple insufficiency fractures after pelvic abscess and sepsis in a rheumatoid arthritis patient treated with high-load corticosteroid therapy: a case report. |
| Q64071210 | Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with |
| Q33188521 | Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. |
| Q37730005 | Teriflunomide and its mechanism of action in multiple sclerosis |
| Q41320881 | The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. |
| Q24800491 | The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes |
| Q34071304 | The final pathogenetic steps in focal bone erosions in rheumatoid arthritis |
| Q35859217 | The treatment of rheumatoid arthritis |
| Q31401575 | The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review |
| Q38380873 | To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology |
| Q37312668 | Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial |
| Q37778588 | Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases |
| Q80089102 | Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy |
| Q41450339 | Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs |
| Q28353468 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine |
| Q34965097 | Treatment of rheumatic diseases in children: special considerations. |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q39815843 | Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal. |
| Q37607063 | Treatment of rheumatoid arthritis: state of the art 2009. |
| Q37158791 | Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review |
| Q46406819 | Treatment with leflunomide in rheumatoid arthritis |
| Q95855555 | Tripterygium Glycosides Combined with Leflunomide for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis |
| Q36723165 | Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway |
| Q43760451 | Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group |
| Q39991278 | Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future |
| Q40253542 | Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience |
| Q35582804 | Use of immunosuppressive agents in uveitis |
| Q45111047 | Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection |
| Q37314965 | Using a simple HPLC approach to identify the enzymatic products of UTL-5g, a small molecule TNF-α inhibitor, from porcine esterase and from rabbit esterase |
| Q30739084 | Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. |
| Q24673434 | When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? |
| Q35024962 | Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? |
| Q82638887 | [Activity-score based therapy in rheumatoid arthritis] |
| Q44679527 | [Drug therapy of rheumatoid arthritis]. |
| Q52895477 | [Therapeutic strategies in rheumatoid arthritis]. |
| Q74101111 | [Treatment of rheumatoid arthritis] |
Search more.